Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S.
Patent 5650405 Issued on July 22, 1997. Estimated Expiration Date: 
June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesPyridine derivatives and their use as anticoccidial agents Rifamycin compounds Pyridine sulfonamides and their use as anticoccidial agents Rifamycin compounds 3-Amidino ansamycins Ansamycin antibiotic and its use as a medicament Azithromycin and derivatives as antiprotozoal agents Treatment of protozoal diseases Treatment for toxoplasmosis Patent #: 5529994 InventorsAssigneeApplicationNo. 481741 filed on 06/07/1995US Classes:514/183, Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI514/256, 1,3-diazines (e.g., pyrimidines, etc.)514/269, Pyrimidines with chalcogen bonded directly to a ring carbon of said pyrimidine moiety514/370, Nitrogen bonded directly to ring carbon of the thiazole ring514/374, 1,3-oxazoles (including hydrogenated)514/601, Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E)514/602Q contains benzene ringExaminersPrimary: Weddington, Kevin E.Attorney, Agent or FirmInternational ClassesA61K 031/33A61K 031/505 A61K 031/425 A61K 031/42 AbstractA method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.Other References
Field of SearchHeterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAISulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E) Q contains benzene ring 1,3-diazines (e.g., pyrimidines, etc.) Pyrimidines with chalcogen bonded directly to a ring carbon of said pyrimidine moiety Nitrogen bonded directly to ring carbon of the thiazole ring 1,3-oxazoles (including hydrogenated) | |
